MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Revance), today announced it has initiated a Phase Ib clinical trial of the Company’s lead drug candidate, a topically delivered botulinum toxin type A gel for the treatment of facial lines and wrinkles. The randomized, placebo-controlled, clinical trial is designed to evaluate clinical response rates in patients with moderate to severe lateral canthal lines (“crow’s feet”).
